Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases
- 10 July 2018
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 17 (9), 873-881
- https://doi.org/10.1016/j.autrev.2018.03.010
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulinJournal of the Peripheral Nervous System, 2011
- Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathyNeurology, 2010
- Intravenous immunoglobulins for steroid‐refractory esophageal involvement related to polymyositis and dermatomyositis: A series of 73 patientsArthritis Care & Research, 2010
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disordersVox Sanguinis, 2010
- Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single‐blinded cross‐over trialEuropean Journal of Neurology, 2009
- A modified peripheral neuropathy scale: the Overall Neuropathy Limitations ScaleJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at homeJournal of Allergy and Clinical Immunology, 2004
- Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costsThe Lancet, 1995
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992